Challenges and perspectives of heart repair with pluripotent stem cell-derived cardiomyocytes

被引：8

作者：

Eschenhagen, Thomas ^{[1
,2
]}

Weinberger, Florian ^{[1
,2
,3
]}

机构：

[1] Univ Med Ctr Hamburg Eppendorf, Inst Expt Pharmacol & Toxicol, Hamburg, Germany

[2] German Ctr Cardiovasc Res DZHK, Partner Site Hamburg Kiel Lubeck, Hamburg, Germany

[3] Ctr Nacl Invest Cardiovasc, Cardiovasc Regenerat Program, Madrid, Spain

来源：

NATURE CARDIOVASCULAR RESEARCH | 2024年 / 3卷 / 05期

基金：

欧盟地平线“2020”; 欧洲研究理事会;

关键词：

MYOCARDIAL-INFARCTION; PROGENITOR CELLS; CARDIAC-MUSCLE; LONG-TERM; TRANSPLANTATION; DIFFERENTIATION; SURVIVAL; MYOCYTES; THERAPY; REMUSCULARIZATION;

D O I：

10.1038/s44161-024-00472-6

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Here we aim at providing a concise but comprehensive overview of the perspectives and challenges of heart repair with pluripotent stem cell-derived cardiomyocytes. This Review comes at a time when consensus has been reached about the lack of relevant proliferative capacity of adult mammalian cardiomyocytes and the lack of new heart muscle formation with autologous cell sources. While alternatives to cell-based approaches will be shortly summarized, the focus lies on pluripotent stem cell-derived cardiomyocyte repair, which entered first clinical trials just 2 years ago. In the view of the authors, these early trials are important but have to be viewed as early proof-of-concept trials in humans that will hopefully provide first answers on feasibility, safety and the survival of allogeneic pluripotent stem cell-derived cardiomyocyte in the human heart. Better approaches have to be developed to make this approach clinically applicable. Eschenhagen and Weinberger provide a concise and comprehensive overview of the perspectives and challenges of heart repair with pluripotent stem cell-derived cardiomyocytes.

引用

页码：515 / 524

页数：10

共 100 条

[51]

Linzbach A J, 1976, Adv Cardiol, V18, P1

[52] HEART FAILURE FROM THE POINT OF VIEW OF QUANTITATIVE ANATOMY [J].